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Identity 
Note: A spectrum of B-cell chronic lymphoproliferative disorders (CLD) may carry a chromosome 13q deletion; among 
these, three forms other than chronic lymphocytic leukemia (CLL) were identified by the FAB group whic may 
frequently carry a 13q- chromosome: atypical CLL, splenic lymphoma with villous lymphocytes, corresponding to 
splenic marginal zone B-cell lymphoma, and mantle cell lymphoma (MCL) in leukemic phase. 
 
Clones dJ1154H7 (top) and dJ1013C9 (bottom) for 13q14 deletions, in normal cells - Courtesy Mariano Rocchi, Resources for Molecular 
Cytogenetics.  
Clinics and pathology 
Disease 
Atypical CLL, including the CLL/PL (prolymphocytic 
leukemia) or CLL mixed-cell-type variant by FAB 
criteria. 
Phenotype/cell stem origin 
Virgin CD5+ recirculating B-cell. 
Epidemiology 
del(13q) is found in approximately 10-15% of all 
CLLs. 
Clinics 
The clinical course may be more aggressive than in 
typical CLL, depending on stage at presentation and % 
of prolymphocytes. 
 
del (13q) in chronic lymphoproliferative diseases Cuneo A 
 




Splenic lymphoma with villous lymphocytes. 
Phenotype/cell stem origin 
Chronic proliferation originating from the marginal 
zone B-lymphocytes. 
Epidemiology 
The disorder appears to be relatively rare, but it is 
probably underdiagnosed. 
Clinics 
The clinical course is indolent. 
Disease 
Leukemic mantle cell lymphoma. 
Note 
The majority of mantle cell lymphomas show 
peripheral blood (PB) involvement at diagnosis or at 
disease evolution; there is a disease variant presenting 
as a de novo leukemic condition, presenting 
heterogeneous cytological features with PB and BM 
lymphocytosis, without adenopathy, with or withour 
splenomegaly; some of these cases may fulfill the FAB 
criteria for the diagnosis of atypical CLL; because th se 
cases usually carry the t(11;14)(q13;q32) and a mantle-
cell phenotype, they have also been referred to as 
'mantle cell leukemia': it is reasonable to assume that
the transformation of a mantle cell may give rise to a 
spectrum of diseases ranging from the classical 
lymphomatous form of MCL to an overt leukemic 
condition, as is the case with small lymphocytic 
lymphoma and chronic lymphocytic leukemia. 
Phenotype/cell stem origin 
Proliferation of cells of follicle mantle lineage 




The frequency of 13q- as an isolated chromosome 
change in atypical CLL is much lower than in typical 
CLL; however FISH studies detected an appoximately 
40% incidence for this anomaly using a 13q14 probe; 
additional chromosome anomaly included +12, 6q- and 
complex karyotypes. 
The incidence of 13q- in splenic marginal zone B-cell 
lymphoma is low by conventional cytogenetic analysis. 
FISH studies detected a 12-47% incidence for cryptic 
13q deletion, the highest frequency having been 
reported using a 13q14 Rb probe; the 13q- is usually 
associated with other chromosome changes, including 
+12, 14q+. 
As is the case with classical MCL, a 40-60% incidence 
for 13q14 deletion was reported in leukemic 
MCL/mantle cell leukemia by interphase FISH. 
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